Episode 262: MRD and ctDNA in Lymphoma With Megan Melody

Returning guest Megan Melody, MD—lymphoma and CAR-T hematologist at Tampa General Hospital and the University of South Florida—joins the show for a practical, data-driven discussion on the evolving role of measurable residual disease (MRD) and circulating tumor DNA (ctDNA) in lymphoma. The conversation explores which lymphoma subtypes benefit most from MRD assessment, the available commercial assays and their sensitivity and specificity, how MRD and PET imaging should be used together (or not), and how to manage real-world scenarios such as PET-positive/ctDNA-negative patients at the end of therapy. Dr. Melody also reviews NCCN guidance, emerging frontline data in large B-cell lymphoma, and how both academic and community clinicians can translate these tools into everyday treatment decisions.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA